J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270008321811v1
48/11/1356    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kearns, G. L.
Right arrow Articles by Paul, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kearns, G. L.
Right arrow Articles by Paul, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

PEDIATRICS

Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents

Gregory L. Kearns, PharmD, PhD, FCP, Jeffrey Blumer, MD, PhD, Stephen Schexnayder, MD, Laura P. James, MD, Kim G. Adcock, PharmD, Michael D. Reed, PharmD, FCP, James F. Daniel, MD, Andrea Gaedigk, PhD and Jeffrey Paul, PhD

From Children's Mercy Hospitals and Clinics and the University of Missouri, Kansas City, Kansas (Dr Kearns, Dr Daniel, Dr Gaedigk); the Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, Ohio (Dr Blumer); Arkansas Children's Hospital Research Institute and University of Arkansas for Medical Sciences, Little Rock, Arkansas (Dr Schexnayder, Dr James); the University of Mississippi Medical Center, Jackson, Mississippi (Dr Adcock); Akron Children's Hospital, Akron, Ohio (Dr Reed); and Wyeth Research, Collegeville, Pennsylvania (Dr Paul).

The primary objective was to determine the pharmacokinetics of single oral and intravenous doses of pantoprazole in children 2 to 16 years of age. The secondary objective was to assess the safety and tolerability of these doses. Male and female hospitalized and nonhospitalized patients from ages 5 to 16 years received single oral doses (20 mg or 40 mg), and those from ages 2 to 16 years received single intravenous doses (0.8 mg/kg or 1.6 mg/kg) of pantoprazole. The plasma concentration-time data for each patient were analyzed using noncompartmental methods. Routine safety and tolerability assessments were also obtained. The mean values for peak plasma concentration and total area under the plasma concentration-time curve increased with increasing dose. Pharmacokinetic values were similar in patients from ages 2 to 16 years and to those previously obtained in adults. Statistically significant differences were observed for dose-normalized pantoprazole area under the plasma concentration-time curve when compared between CYP2C19 extensive metabolizers with 1 versus 2 functional alleles. All adverse events were mild in severity and considered to be unrelated to study drug. The pharmacokinetic profile of oral and intravenous pantoprazole was similar in children ages 2 to 16 years. The doses used here were safe and well tolerated in this population.

Key Words: Pharmacokinetics • children • pantoprazole • safety

Address for reprints: Gregory L. Kearns, PharmD, PhD, Division of Pediatric Pharmacology and Medical Toxicology, The Children's Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108; e-mail: gkearns{at}cmh.edu.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology